跳至主要内容
临床试验/CTRI/2025/11/097165
CTRI/2025/11/097165尚未招募不适用

Effect of Platelet-Rich Plasma Combined with Supervised Strengthening Exercise on Pain in Knee Osteoarthritis

Sree Pallob1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2025年12月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
120
试验地点
1

研究概览

简要总结

This randomized controlled trial investigates the effect of Platelet-Rich Plasma (PRP) combined with a supervised strengthening exercise program on pain and functional outcomes in knee osteoarthritis (OA). The experimental group will receive three intra-articular PRP injections and participate in an 8-week supervised exercise program. The control group will only undergo the exercise program. Primary and secondary outcomes will include pain intensity (Numeric Pain Rating Scale), functional performance (WOMAC), range of motion, muscle strength (digital dynamometer), and functional mobility (Timed Up and Go). Inclusion criteria involve individuals aged 50+ with mild to moderate knee OA.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Outcome Assessor Blinded

入排标准

年龄范围
50.00 Year(s) 至 75.00 Year(s)(—)
性别
All

入选标准

  • Participants aged fifty years or older with a clinical diagnosis of knee osteoarthritis for at least six months according to the American College of Rheumatology criteria will be included.
  • Eligible individuals must report an average knee pain score of four or higher on an eleven-point numerical rating scale over the past week and show mild to moderate radiographic tibiofemoral osteoarthritis defined as Kellgren and Lawrence grade two or three.
  • All participants must provide informed consent and agree to participate in the eight-week study intervention.

排除标准

  • Participants will be excluded if they show greater lateral than medial joint space narrowing on radiographs.
  • Other exclusion criteria include the presence of systemic or inflammatory diseases, a history of glucocorticoid injection within the past three months, hyaluronic acid injection within the past six months, previous treatment with autologous blood products or stem cell therapy, platelet count one hundred fifty thousand per microliter or lower, bleeding disorders, or ongoing anticoagulant therapy.
  • For bilateral knee osteoarthritis, only the most symptomatic knee will be treated.

研究者

发起方
Sree Pallob
申办方类型
Other [self-funded]
责任方
Principal Investigator
主要研究者

Sree Pallob

Jashore University of Science and Technology

研究点 (1)

Loading locations...

相似试验